
Given subcutaneously every 3 months, cemdisiran (Livsayis) is indicated for adults with AChR antibody–positive gMG and requires REMS enrollment.
Miglustat (Zavesca) is indicated for the treatment of mild to moderate type I Gaucher disease.
Medication Pearl of the Day: Miglustat (Zavesca)
Indication: Miglustat is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for the first step in the synthesis of most glycosphingolipids. The drug is indicated for the treatment of mild to moderate type I Gaucher disease.
Insight:
Sources:






